image of Clinical Handbook of Psychotropic Drugs

Clinical Handbook of Psychotropic Drugs

Publication Year:
2023
Edition:
25th Ed.
Author:
Ric M. Procyshyn, Kalyna Z. Bezchlibnyk Butler, David D. Kim
Publisher:
Hogrefe Publishing GmbH
ISBN:
978-0-88-937632-8
Doody's Star Rating®:
Score:
97
Print/PDF
Request Info
Add to Ovid Subscription
Access the Book in Ovid
Access the Book in Ovid
  • Description
  • Details
  • Collections
  • Also Recommended
Description

Quick and comprehensive information on psychotropic drugs for adults.


  • Accurate and up-to-date

  • Comparison charts help decision-making

  • Icons with full color

  • Available both in print and online

  • Downloadable patient information sheets


    • More about this book
    The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.

  • Independent, unbiased, up-to-date

  • Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options

  • Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug

  • Potential interactions and side effects summarized in comparison charts

  • With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek

  • Clearly written patient information sheets available for download as printable PDF files

    • This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.

    New in this edition

  • Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion)

  • Antipsychotics updates include revised clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia

  • Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised

  • Dementia chapter includes a new section on lecanemab, a new fast-track FDA-approved treatment for Alzheimer’s disease

  • Treatment of Substance Use Disorders includes revisions to buprenorphine dosing section that include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal

  • Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetics chapters all substantially revised

  • New formulations and trade names include: Auvelity (dextromethorphan/bupropion extended-release tablets), Invega Hafyera (paliperidone 6-monthly IM injection), Leqembi (lecanemab infusion), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)
    • Details
    Platform:
    OvidSP
    Publisher:
    Hogrefe Publishing GmbH
    Product Type:
    Book
    Author:
    Ric M. Procyshyn, Kalyna Z. Bezchlibnyk Butler, David D. Kim
    ISBN:
    978-0-88-937632-8
    Specialty:
    • Pharmaceuticals
    Language:
    English
    Edition:
    25th Ed.
    Pages:
    522
    Publication Year:
    2023
    Doody's Star Rating®:
    Score:
    97

    Request Information

    Rely on Ovid as the trusted solution that transforms research into results.
    Back To Top